Summary
Zydus Lifesciences has received final USFDA approval for its generic ascorbic acid injection, intended for treating scurvy in specific patient populations. This product is the generic equivalent of the Ascor injection and was designated as a Competitive Generic Therapy by the USFDA, allowing Zydus to market it in the United States.